Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer

PURPOSE: Phosphatidylinositol 3-kinase (PI3K) inhibitors are being developed for the treatment of estrogen receptor α (ER)-positive breast cancer in combination with anti-estrogens. Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER+ breast cancer will provide r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yang, Wei, Hosford, Sarah R., Dillon, Lloye M., Shee, Kevin, Liu, Stephanie C., Bean, Jennifer R., Salphati, Laurent, Pang, Jodie, Zhang, Xiaolin, Nannini, Michelle A., Demidenko, Eugene, Bates, Darcy, Lewis, Lionel D., Marotti, Jonathan D., Eastman, Alan R., Miller, Todd W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854767/
https://ncbi.nlm.nih.gov/pubmed/26733612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados